CTOs on the Move

BrainsWay

www.brainsway.com

 
BrainsWay is an Israeli company with international operations that is engaged in the development of a medical device that uses H-coil for deep transcranial magnetic stimulation as a noninvasive treatment for depression.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.brainsway.com
  • 1 Van de Graaff Drive Suite 405
    Burlington, MA USA 01803
  • Phone: 844.386.7001

Executives

Name Title Contact Details

Similar Companies

Tishcon Corp

Tishcon Corp is a Salisbury, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Hart Design Group

Hart Design Group is a Cumberland, RI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Mobile Physician Services

Mobile Physician Services is a practice of doctors and nurse practitioners who make house calls to homebound patients. We specialize in the treatment of patients with complex medical needs. MPS is one of the only house call practices in the United Sta...

BELLWYCK PACKAGING SOLUTIONS

BELLWYCK PACKAGING SOLUTIONS is a Owen Sound, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

La Jolla Pharmaceutical Company

La Jolla Pharmaceutical Company is a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases. The Company has four product candidates in development. LJPC-501 is La Jolla’s proprietary formulation of angiotensin II for the potential treatment of catecholamine-resistant hypotension and hepatorenal syndrome. GCS-100 is La Jolla’s first-in-class galectin-3 inhibitor for the potential treatment of chronic kidney disease. LJPC-1010, La Jolla’s second-generation galectin-3 inhibitor, is a more potent and purified derivative of GCS-100 that can be delivered orally for the potential treatment of nonalcoholic steatohepatitis and other diseases characterized by tissue fibrosis. LJPC-401 is La Jolla’s novel formulation of hepcidin for the potential treatment of conditions characterized by iron overload, such as hemochromatosis and beta thalassemia